Literature DB >> 29447328

Cardiac surgery in adult patients with remitted or active malignancies: a review of preoperative screening, surgical management and short- and long-term postoperative results.

Roberto Lorusso1, Enrico Vizzardi2, Daniel M Johnson1, Giovanni Mariscalco3, Edoardo Sciatti2, Jos Maessen1, Elham Bidar1, Sandro Gelsomino1.   

Abstract

Candidate patients for cardiac surgery procedures with a history of malignancies and antitumour therapy or with an active cancer and on antineoplastic treatment are increasingly common in daily practice. Oncological therapy can lead to cardiovascular injury and, therefore, has the potential for impacting operative risks and surgical strategies. This means that a number of considerations are essential to take into account prior to cardiac surgery. These include the type of cancer, previous cardiotoxicity or concomitant antitumour therapy, reversibility or irreversibility of such complications, the interaction between cancer disease course and extracorporeal circulation, the need for associated surgery and the impact of cancer on early and long-term outcomes. Adequate preoperative evaluation of cardiovascular abnormalities potentially related to antineoplastic therapy and proper diagnostic workup of other conditions linked to the type of cancer (e.g. haematological disorders and lung dysfunction) are therefore of paramount importance for appropriate surgical decision-making. Careful evaluation of the association of cardiovascular disease to be treated and the prognosis of remitted or active cancer should be established to enhance the prediction of early, medium and long-term outcomes and for a more correctly informed patient. Furthermore, if the prognosis of operated patients appears unfavourable, then alternative therapeutic strategies can be applied without significant delay. The aim of this review is to give an overview of factors that should be considered in adult patients who are undergoing, or have undergone, treatment for oncological indications who are candidates for cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29447328     DOI: 10.1093/ejcts/ezy019

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  National perspective on hospital readmissions following adrenalectomy.

Authors:  Mohammed Hussein; Eman Toraih; Ahmed Mahmoud Fouad; Lauren Mueller; Alexander Blum; Zaid Al-Qurayshi; Jeffrey Borchardt; Emad Kandil
Journal:  Gland Surg       Date:  2022-06

2.  Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock-Analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Mariusz Kowalewski; Kamil Zieliński; Daniel Brodie; Graeme MacLaren; Glenn Whitman; Giuseppe M Raffa; Udo Boeken; Kiran Shekar; Yih-Sharng Chen; Christian Bermudez; David D'Alessandro; Xiaotong Hou; Jonathan Haft; Jan Belohlavek; Inga Dziembowska; Piotr Suwalski; Peta Alexander; Ryan P Barbaro; Mario Gaudino; Michele Di Mauro; Jos Maessen; Roberto Lorusso
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 9.296

3.  Combined Coronary Artery Bypass Grafting, Aortic, and Lung Carcinoma Surgery.

Authors:  Nora Goebel; Ulrich F W Franke
Journal:  Thorac Cardiovasc Surg Rep       Date:  2020-05-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.